VIEW MORELeading experts update on the role and relevance of consortia in the delivery of precision oncology early phase clinical trials
VIEW MOREVHIO’s Director Josep Tabernero elected to the 2025 class of Fellows of the American Association for Cancer Research Academy
VIEW MORERadioligand therapy demonstrates improved clinical benefit in patients with gastroenteropancreatic neuroendocrine tumors vs. molecular targeted therapy
Latest News
26 March 2025
Vall d’Hebron shows long-term safety of CAR-T therapy in aggressive lymphoma patients
The results show the need for continuous monitoring of patients to detect and manage possible adverse effects occurring months and...
18 March 2025
Leading experts update on the role and relevance of consortia in the delivery of precision oncology early phase clinical trials
Co-authored by leading experts in oncology, a review article recently published in the Journal of Clinical Oncology (JCO)* provides an...
10 March 2025
VHIO’s Director Josep Tabernero elected to the 2025 class of Fellows of the American Association for Cancer Research Academy
The American Association for Cancer Research (AACR) has officially announced this year’s class of Fellows of the AACR Academy. The...
06 March 2025
Radioligand therapy demonstrates improved clinical benefit in patients with gastroenteropancreatic neuroendocrine tumors vs. molecular targeted therapy
Initial results of the COMPETE phase 3 clinical trial—the first study to compare targeted radioligand therapy with molecular targeted therapy...
PRINCIPAL RESEARCHERS
Events
Thursday 13 November 25 - 09:00 AM
2nd VHIO-BBVA Foundation Symposium on Cell-Based Therapies in Oncology
Thursday 10 April 25 - 03:00 PM
CCE Lecture: Dissecting the function of copy number alterations in cancer
